Disufenton

Drug Profile

Disufenton

Alternative Names: Cerovive; CPI 22; Disufenton sodium; NXY 059; NXY 059G

Latest Information Update: 01 Nov 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Renovis
  • Class Anti-ischaemics; Benzenesulfonates; Neuroprotectants; Nitrogen oxides; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 01 Nov 2006 Results from the phase III clinical trial SAINT II in patients with acute ischaemic stroke have been added to the adverse events and Neurological disorders therapeutic trials sections ,
  • 26 Oct 2006 Discontinued - Phase-III for Stroke in Asia, Australia, Canada, Europe, New Zealand, South Africa, South America, Sweden, United Kingdom, USA and Japan (IV-infusion)
  • 02 Aug 2006 Renovis has completed enrolment in the SAINT II trial for acute ischaemic stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top